03316nam 2200961z- 450 991055761010332120231214133507.0(CKB)5400000000045301(oapen)https://directory.doabooks.org/handle/20.500.12854/79654(EXLCZ)99540000000004530120202203d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPharmacogenetics to Avoid Adverse Drug ReactionsBaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (220 p.)3-0365-3344-3 3-0365-3343-5 Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.Medicinebicssc5-fluorouracilcapecitabinefluoropyrimidinethymidylate synthasethymidylate synthase enhancer regionupstream stimulatory factor 1adverse drug reactionspharmacogenomicsepistasisrandom foreststatincardiovascular diseasecolorectal cancerpersonalised medicinetoxicity(es)citalopramdrug-gene-interactiondrug-drug-interactiondrug-drug-gene-interactionthe PharmLines initiativeantipsychotic agentspharmacogeneticscytochrome P-450 enzyme systempsychotic disordersprecision medicinedirect oral anticoagulantsclinical implementationatorvastatinSLCO1B1HLAcutaneous adverse drug reactionSCARgenetic polymorphismantiepilepticsCYP450 enzymesplatelet reactivitysingle-nucleotide variantsacute coronary syndromeclopidogrelgenotypeallelepolymorphismHLA BCYP2C9*3cutaneous adverse drug reactions (CADRs)anti-epileptic drugs (AEDS)phenytoin (PHT)genetic risk factorsSouth IndiaIndiacardiologyadverse eventsguidelinesMedicineLópez-Fernández Luis Aedt1319399López-Fernández Luis AothBOOK9910557610103321Pharmacogenetics to Avoid Adverse Drug Reactions3033877UNINA